Class Action Lawsuit Filed Against Cytokinetics, Incorporated

Strategic Insights -

Investors in Cytokinetics, Incorporated have been notified of a class action securities lawsuit alleging securities fraud between December 27, 2023 and May 6, 2025. The lawsuit seeks to recover losses suffered by investors who were allegedly misled about the timeline for the New Drug Application ("NDA") submission and approval process for aficamten. The complaint alleges that defendants made false and misleading statements about the regulatory process, including the representation that the Company expected approval from the U.S. Food and Drug Administration ("FDA") in the second half of 2025. However, it was later revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation, but chose to submit the NDA without a Risk Evaluation and Mitigation Strategy ("REMS").

Key Takeaways:

  • The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023 and May 6, 2025.
  • Defendants made materially false and misleading statements regarding the timeline for the NDA submission and approval process for aficamten.
  • The Company represented that the FDA expected approval of the NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date.
  • The complaint alleges that the Company's decision to omit a REMS from the initial submission was reckless and misleading to investors.
  • Investors who suffered losses in Cytokinetics may be entitled to compensation without payment of any out-of-pocket costs or fees.
  • The law firm Levi & Korsinsky, LLP is representing the investors in the class action lawsuit.

Statistics:

  • The class action lawsuit was filed on October 28, 2025.
  • The financial losses suffered by investors due to alleged securities fraud amount to significant sums of money.
  • The complaint alleges that the Company's false and misleading statements caused investors to purchase Cytokinetics' common stock at artificially inflated prices.
  • The case details involve a 35-month period from December 27, 2023 to May 6, 2025.

Sources:

  • GlobeNewswire: "Levi & Korsinsky, LLP Notifies Investors of Class Action Lawsuit Against Cytokinetics, Incorporated (NASDAQ: CYTK)" (October 28, 2025)
  • Comtex 469868879: "Levi & Korsinsky, LLP Notifies Investors of Class Action Lawsuit" (October 28, 2025)